For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A phase II randomized study of adjuvant vs. neoadjuvant MK-3475 (Pembrolizumab) for clinically detectable stage III-IV high-risk melanoma
To compare outcomes of receiving the study drug either before and after or only after surgery.
DiagnosisHave stage III or IV resectable melanoma in order to be eligible for this study.
Must not have received previous neoadjuvant treatment for their melanoma. Patients may have received prior non-immunotherapy adjuvant therapy.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- ARM I: Adjuvant Arm. Will first undergo surgery, then a few weeks later, will receive pembrolizumab for approximately one year (18 total doses).
- ARM II: Neoadjuvant Arm. Will receive pembrolizumab for a couple months (3 doses) and then have surgery a few weeks later. After recovery from surgery, patients will receive additional pembrolizumab (15 doses), totaling together 18 doses for before and after surgery.
For more information, visit ClinicalTrials.gov